Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Non-invasive prenatal testing (NIPT) is an innovative way of screening pregnancies for fetal chromosomal aneuploidies by analyzing fetal cell-free DNA circulating in maternal blood. It involves the testing for particular diseases or birth defects in a fetus or embryo before it is born.

Statistics:

The global non-invasive prenatal testing market is estimated to account for US$ 1,936.4 Mn in terms of value by the end of 2027.

Global Non-Invasive Prenatal Testing Market: Drivers

High prevalence of chromosomal disorders is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, according to the study, ‘Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea’, published in Journal of Korean Medical Science in August 2019, the prevalence of live births with Down’s syndrome was 5.03 per 10,000 births between 2007 and 2016.

Moreover, high awareness regarding benefits of non-invasive testing methods is also expected to aid in growth of the global non-invasive prenatal testing market. Obstetricians are increasingly recommending patients to undergo non-invasive tests as an alternative to invasive methods and initial diagnostic screening in the first trimester of a pregnancy.

Statistics:

North America held dominant position in the global non-invasive prenatal testing market in 2019, accounting for 45% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Non-Invasive Prenatal Testing Market Share (%) Value, By Region, 2019

Non-Invasive Prenatal Testing  | Coherent Market Insights

Global Non-Invasive Prenatal Testing Market: Restraints

Uncertain reimbursement policies and insurance coverage is expected to hinder growth of the global non-invasive prenatal testing market. Changes in the American Medical Association’s Current Procedural Terminology, or CPT codes for non-invasive tests along with other molecular diagnostic testing have led to uncertainties in reimbursement and insurance coverage for these tests. Given the high costs for these tests, most vendors enjoy limited success due to limited or no coverage for these tests.

Moreover, tests are patented by select few vendors, which is also expected to limit growth of the market. A very select few vendors hold patents and exclusive licenses to technologies used in non-invasive prenatal tests. As a result, there is limited market competition and limited incentive to reduce cost of testing, as well as quality assurance.

request-sample

Non-Invasive Prenatal Testing Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 971.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 10.3% 2027 Value Projection: US$ 1,936.4 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Test Type: Panel 1 Test, Panel 2 Test, Panel 3 Test.
  • By End User: Hospitals, Diagnostic Laboratories, Maternity Centers.
Companies covered:

Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia, BillionToOne, Inc., and Quest Diagnostics Incorporated

Growth Drivers:
  • Increasing prevalence of chromosomal disorders
  • Approval and launch of new products
Restraints & Challenges:
  • Lack of reimbursement

Global Non-Invasive Prenatal Testing Market: Opportunities

Obtaining reimbursement for tests from payers is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market. Vendors may focus on obtaining insurance coverage for NIPT tests offered by them, considering the high costs of these tests.

Moreover, attention towards health education, subsidies for NIPT, and genetic counseling is also expected to aid in growth of the market. For instance, in September 2020, researchers from Fudan University, China, and University College London, U.K., reported that, in China, compared with Zhengzhou participants, a higher proportion of Shenzhen women had heard of NIPT (87.30% vs. 64.03%), were willing to receive NIPT (91.80% vs. 80.43%) and had taken NIPT (83.12% vs. 54.54%), while their satisfaction level was lower.

Statistics:

The global non-invasive prenatal testing market was valued at US$ 882.9 Mn in 2019 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027.

Figure 2: Global Non-Invasive Prenatal Testing Market Value (US$ Mn), 2016 – 2027

Non-Invasive Prenatal Testing  | Coherent Market Insights

Market Trends/Key Takeaways

Recommendation of new guidelines is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, in August 2020, American College of Obstetricians and Gynecologists recommend new guidelines for Non-Invasive Prenatal Testing (NIPT).

Major players in the global non-invasive prenatal testing market are focused on raising funds to enhance their market share. For instance, in March 2020, BillionToOne, Inc. raised US$ 15 million to support the commercial expansion of UNITY, a prenatal screen that directly assesses the baby’s risk for common and severe inherited disorders such as cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to all US states as well as the research and development (R&D) of future diagnostics tests including liquid biopsy products.

Regulations

Europe

  • A national screening program for congenital anomalies or aneuploidies is strictly avoided in Europe, because doctors and the national health service are NOT interested in terminating as many handicapped individuals as possible
  • But pregnant women are informed in time by the obstetricians about the existence of all the prenatal tests available, mentioning the advantages, the related risks and possible difficult decisions arising from these tests
  • All these non-invasive / risk calculation tests and invasive / diagnostic tests are offered on request of the pregnant women and are not compulsory. Since Combined Tests are increasingly requested, the number of invasive tests is significantly declining.
  • Reimbursement Scenario for NIPT - Health insurer Anthem Blue Cross Blue Shield changed its medical policy regarding non-invasive prenatal testing as such screening technology is considered medically necessary for most pregnancies regardless of the risk status. According to Anthem's new policy, cell-free DNA-based prenatal screening for trisomy 21, 18, and 13 is medically necessary for women carrying a single fetus using NIPT as a screening tool for fetal aneuploidies regardless of risk status.

Global Non-Invasive Prenatal Testing Market: Competitive Landscape

Major players operating in the global non-invasive prenatal testing market include, Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia,  BillionToOne, Inc., and Quest Diagnostics Incorporated.

Global Non-Invasive Prenatal Testing Market: Key Developments

Major players in the global non-invasive prenatal testing market are focused on launching new products to expand their product portfolio. For instance, in August 2019, Axia Women’s Health, a U.S. based independent women’s healthcare group, launched non-invasive prenatal testing (NIPT) in U.S.

Non-invasive prenatal testing (NIPT) is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome. During non-invasive prenatal testing DNA from the mother and fetus is extracted from maternal blood sample and it is recommended for women who have risk factors for having a baby who has a chromosomal condition. Increasing launches and approvals of new non-invasive prenatal tests (NIPT) along with increasing prevalence of chromosomal disorders is expected to propel the market growth during the forecasted period.

Key features of the study:

  • This report provides in-depth analysis of the Global Non-Invasive Prenatal Testing market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Non-Invasive Prenatal Testing market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia, BillionToOne, Inc., and Quest Diagnostics Incorporated
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Non-Invasive Prenatal Testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Non-Invasive Prenatal Testing market

Detailed Segmentation:

  • Global Non-Invasive Prenatal Testing Market, By Test Type:
    • Panel 1 Test
    • Panel 2 Test
    • Panel 3 Test
  • Global Non-Invasive Prenatal Testing Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Maternity Centers
  • Global Non-Invasive Prenatal Testing Market, By Region:
    • North America
      • By Test Type:
        • Panel 1 Test
        • Panel 2 Test
        • Panel 3 Test
      • By End User
        • Hospitals
        • Diagnostic Laboratories
        • Maternity Centers
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Test Type:
        • Panel 1 Test
        • Panel 2 Test
        • Panel 3 Test
      • By End User
        • Hospitals
        • Diagnostic Laboratories
        • Maternity Centers
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Test Type:
        • Panel 1 Test
        • Panel 2 Test
        • Panel 3 Test
      • By End User
        • Hospitals
        • Diagnostic Laboratories
        • Maternity Centers
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Test Type:
        • Panel 1 Test
        • Panel 2 Test
        • Panel 3 Test
      • By End User
        • Hospitals
        • Diagnostic Laboratories
        • Maternity Centers
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Test Type:
        • Panel 1 Test
        • Panel 2 Test
        • Panel 3 Test
      • By End User
        • Hospitals
        • Diagnostic Laboratories
        • Maternity Centers
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Test Type:
        • Panel 1 Test
        • Panel 2 Test
        • Panel 3 Test
      • By End User
        • Hospitals
        • Diagnostic Laboratories
        • Maternity Centers
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Ariosa Diagnostics, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • BGI Diagnosis Co., ltd.
    • Berry Genomics Corporation
    • Illumina, Inc.
    • LifeCodexx AG
    • Natera, Inc.
    • Sequenom, Inc.
    • Natera, Inc.
    • Axia Women’s Health
    • Eluthia
    • BillionToOne, Inc.
    • Quest Diagnostics Incorporated
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Test Type
      • Market Snippet, By End User
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
    • COVID19 Impact on the market
  4. Global Non-Invasive Prenatal Testing Market, By Test Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Panel 1 Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Panel 2 Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Panel 3 Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Non-Invasive Prenatal Testing Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Maternity Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Non-Invasive Prenatal Testing Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Ariosa Diagnostics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BGI Diagnosis Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Berry Genomics Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Illumina, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • LifeCodexx AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Natera, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sequenom, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Natera, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Axia Women’s Health
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eluthia
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BillionToOne, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Quest Diagnostics Incorporated
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 20 market data tables and 12 figures on “Non-Invasive Prenatal Testing Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Non-Invasive Prenatal Testing market size was estimated at US$ 882.9 million in 2020 and is estimated to exhibit a CAGR of 10.3% between 2020 and 2027.
Panel 1 Test segment held the major market share in Global Non-Invasive Prenatal Testing market during 2019 .
Major factor driving the growth of Global Non-Invasive Prenatal Testing market during the forecast period comprises of high prevalence of chromosomal disorders is expected to propel, increasing research & development, and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Non-Invasive Prenatal Testing market during the forecast period constitutes of uncertain reimbursement policies and insurance coverage.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia, BillionToOne, Inc., and Quest Diagnostics Incorporated.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner